Applied Therapeutics Inc logo

APLT - Applied Therapeutics Inc Share Price

$20.85 -0.9  -4.0%

Last Trade - 01/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £388.5m
Enterprise Value £304.9m
Revenue £n/a
Position in Universe 3412th / 6633
Bullish
Bearish
Unlock APLT Revenue
Momentum
Relative Strength (%)
1m -1.40%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AppliedTherapeutics Inc revenues was not reported. Net lossincreased from $27.9M to $70.3M. Higher net loss reflectsResearch and development - Balancing val increase from$14.5M to $43.5M (expense), Legal & professional expensesincrease from $3.2M to $6.6M (expense), Stock-basedCompensation in SGA increase of 24% to $3.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for APLT
Graphical History

Revenue

APLT Revenue Unlock APLT Revenue

Net Income

APLT Net Income Unlock APLT Revenue

Normalised EPS

APLT Normalised EPS Unlock APLT Revenue

PE Ratio Range

APLT PE Ratio Range Unlock APLT Revenue

Dividend Yield Range

APLT Dividend Yield Range Unlock APLT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APLT EPS Forecasts Unlock APLT Revenue
Profile Summary

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 20, 2016
Public Since May 9, 2019
No. of Shareholders: 125
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 25,943,661
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APLT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APLT
Upcoming Events for APLT
Frequently Asked Questions for Applied Therapeutics Inc
What is the Applied Therapeutics Inc share price?

As of 01/03/21, shares in Applied Therapeutics Inc are trading at $20.85, giving the company a market capitalisation of £388.5m. This share price information is delayed by 15 minutes.

How has the Applied Therapeutics Inc share price performed this year?

Shares in Applied Therapeutics Inc are currently trading at $20.85 and the price has moved by -49.82% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Applied Therapeutics Inc price has moved by -59.31% over the past year.

What are the analyst and broker recommendations for Applied Therapeutics Inc?

There are no analysts currently covering Applied Therapeutics Inc.

When will Applied Therapeutics Inc next release its financial results?

Applied Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Applied Therapeutics Inc dividend yield?

Applied Therapeutics Inc does not currently pay a dividend.

Does Applied Therapeutics Inc pay a dividend?

Applied Therapeutics Inc does not currently pay a dividend.

When does Applied Therapeutics Inc next pay dividends?

Applied Therapeutics Inc does not currently pay a dividend.

How do I buy Applied Therapeutics Inc shares?

To buy shares in Applied Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Applied Therapeutics Inc?

Shares in Applied Therapeutics Inc are currently trading at $20.85, giving the company a market capitalisation of £388.5m.

Where are Applied Therapeutics Inc shares listed? Where are Applied Therapeutics Inc shares listed?

Here are the trading details for Applied Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: APLT
What kind of share is Applied Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Applied Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Applied Therapeutics Inc share price forecast 2021?

Shares in Applied Therapeutics Inc are currently priced at $20.85. At that level they are trading at 0.139% discount to the analyst consensus target price of 0.00.

Analysts covering Applied Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.534 for the next financial year.

How can I tell whether the Applied Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -22.34%. At the current price of $20.85, shares in Applied Therapeutics Inc are trading at -21.94% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Applied Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Applied Therapeutics Inc.

Who are the key directors of Applied Therapeutics Inc?

Applied Therapeutics Inc's management team is headed by:

Shoshana Shendelman - CHM
Leslie Funtleyder - DRC
Joel Marcus - DRC
Teena Lerner - DRC
Stacy Kanter - IND
Jay Skyler - IND
Mark Vignola - CFO
Riccardo Perfetti - OTH
Who are the major shareholders of Applied Therapeutics Inc?

Here are the top five shareholders of Applied Therapeutics Inc based on the size of their shareholding:

Shendelman (Shoshana) Individual Investor
Percentage owned: 18.83% (4.88m shares)
Alexandria Real Estate Equities, Inc. Investment Advisor
Percentage owned: 13.07% (3.39m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 8.57% (2.22m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.83% (1.77m shares)
Emerald Advisers LLC Investment Advisor
Percentage owned: 4.07% (1.06m shares)
Similar to APLT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.